[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100444171":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":37,"locations":45,"responsibleParty":62,"collaborators":10,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":81,"studyType":82,"phases":10,"briefSummary":83,"conditions":84,"keywords":88,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Aarhus University Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Chronic Heart Failure",null,"Patients with heart failure with preserved, mid-range or reduced ejection fraction (NYHA I-IV) according to European Society of Cardiology guidelines.",{"label":13,"type":10,"description":14,"interventionNames":10},"Controls","Age and sex matched control group. Individuals with no history of cardiovascular disease or severe lung, musculoskeletal or neurological disease.",[16,19,21,24,26,28,31,33,35],{"name":17,"affiliation":5,"role":18},"Henrik Wiggers, Prof.","STUDY_CHAIR",{"name":20,"affiliation":5,"role":18},"Andreas B Tinggaard, MD",{"name":22,"affiliation":23,"role":18},"Søren P Johnsen, Prof.","Aalborg University Hospital",{"name":25,"affiliation":5,"role":18},"Helene Nørrelund, Ass. Prof.",{"name":27,"affiliation":5,"role":18},"Anders H Larsen, MD, PhD",{"name":29,"affiliation":30,"role":18},"Peter Leutscher, Prof.","Regionshospital Nordjylland",{"name":32,"affiliation":30,"role":18},"Peter B Stæhr, MD, PhD",{"name":34,"affiliation":30,"role":18},"Steen H Jørgensen, MD",{"name":36,"affiliation":5,"role":18},"Niels Jessen, Prof.",[38,42],{"name":17,"role":39,"phone":40,"phoneExt":10,"email":41},"CONTACT","+45 2275 3202","henrikwiggers@dadlnet.dk",{"name":20,"role":39,"phone":43,"phoneExt":10,"email":44},"+45 3027 2717","andreas.bugge@midt.rm.dk",[46],{"facility":5,"status":47,"city":48,"state":10,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Aarhus N","8200","Denmark","DK",{"type":53,"coordinates":54},"Point",[55,56],10.17317,56.20367,{"lat":56,"lon":55},[59,61],{"name":20,"role":39,"phone":60,"phoneExt":10,"email":44},"30272717",{"name":17,"role":39,"phone":10,"phoneExt":10,"email":41},{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Henrik Wiggers","Professor","100444171","mechanism-of-sarcopenia-in-heart-failure-100444171",false,"NCT05063955","Mechanism of Sarcopenia in Heart Failure","Socioeconomic Factors and Mechanisms of Sarcopenia and Muscle Strength in Chronic Heart Failure Patients","MUSCLE-CHF","Inclusion Criteria:\n\n1. Ability to provide valid informed consent.\n2. Heart failure with preserved, mid-range or reduced ejection fraction (NYHA I-IV) according to European Society of Cardiology guidelines.\n\nExclusion Criteria:\n\n1. Cancer requiring treatment (e.g. prostate cancer on watchful waiting does not exclude patients).\n2. Severe musculoskeletal or neurological disability.\n3. Severe lung disease with a forced expiratory volume 1 \\\u003C 40% of predicted. Treatment with anticoagulants (warfarin, apixaban, edoxaban, dabigatran and rivaroxaban) is an exclusion criterion for muscle biopsy. Patients with anticoagulant treatment will be invited to participate in the study without muscle biopsy.\n4. Other comorbidities that prevent the patient from participating in the study examinations as judged by the investigator.",true,"ALL","18 Years","90 Years",{"count":79,"type":80},250,"ESTIMATED","10 Years","OBSERVATIONAL","The aim of the study is to provide information on the interaction between socioeconomic factors, daily physical activity, nutrition and lifestyle on loss of muscle mass and muscle function in patients with heart failure.",[85,86,87],"Heart Failure","Sarcopenia","Cachexia",[89,86,87],"Heart failure","2023-12-19",{"date":92,"type":93},"2023-12-26","ACTUAL",{"date":95,"type":93},"2020-12-02",{"date":97,"type":80},"2033-12-31",{"name":5,"class":6},1]